Recent research have focused on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopamine neurotransmission. While GIP activators are commonly employed for addressing type 2 diabetes, their unexpected effects on motivation circuits, specifically governed by dopamine pathways, are attracting significan